home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Corel Medical Series: Cancer
/
Corel Medical Series: Cancer.iso
/
mac
/
Program
/
c18.dxr
/
00101_Field_SRC.c18.A.14.txt
< prev
next >
Wrap
Text File
|
1997-01-28
|
1KB
|
15 lines
• Investigational Treatment with other, more experimental, agents can also try to "push" the leukemic cells in
the direction of normal cells in appearance and function. Investigative agents now being evaluated include
growth factors or cytokines such as G-CSF (granulocyte colony stimulating factor), a new synthetic chemical
agent called HMBA (hexamethylene bisacetamide), IL-3 (interleukin-3) or vitamin A analogues (retinoic acid).
It is too soon to know how effective these innovative treatments are.
• Intensive chemotherapy When the preleukemic stage becomes similar to an acute leukemia—in other words, it
becomes a more aggressive form with survival a matter of months—standard therapy is similar to that
described for acute leukemia.
• Bone Marrow Transplantation Even though bone marrow transplantation has been available for the past 15
years, it is still a new type of management. In several large studies on allogeneic marrow transplantations for
young patients with myelodysplastic syndrome, there seems to be some indication that approximately half the
patients may obtain a long-term disease-free survival. This is still an investigational treatment.